Steven Niedelman, Lead Quality Systems and Compliance Consultant, King & Spalding, provided an extensive overview of FDA inspections during the May 28 Govilla webinar, “Guess Who’s Knocking At Your Door: Assuring Inspection Success!” Parts I and II of this series covered FDA’s authority to inspect, the types of inspections conducted, and what FDA investigators can and cannot review when onsite.

An Ounce of Preparation

So, FDA investigators are at the gate. What can you expect during the inspection? And how can you prepare in advance to ensure a smooth inspection?

Niedelman offered the following advice for how companies can prepare for an FDA inspection long before investigators are at the gate. 

  • Train the personnel responsible for access to the site, even security guards and receptionists, to inform the appropriate individuals that “FDA is here.” There should be a call down list with critical contacts. Front-facing personnel should be trained to tell the investigator to have a seat until somebody comes. 
  • Conduct mock audits to ensure staff members understand their roles in an inspection. For example, IT will need to set up conference rooms and computers for investigators.
  • Keep organizational charts up to date.
  • Ensure you have a current opening presentation about your firm that includes the floor plan and who is responsible for manufacturing product.
  • Develop a demo of the product or device manufactured onsite.
  • Make sure you have copies of current procedures available. 

Once the investigators are onsite, ascertain the scope of the inspection. Is it a routine surveillance inspection? Or is it a for-cause inspection? 

Get your CFR Trend Report from Redica

“It may start as a typical routine surveillance inspection,” Niedelman said. “Over time as things develop or [inspectors] find things, they may decide to focus in different areas. If it is a medical device firm, those inspections are typically preannounced three to five days in advance and you can ask the purpose of the inspection.”

Once you have the name of the investigator, Niedelman recommended looking up their profile in Govzilla along with asking your network about their experience with that particular inspector. 

What to Expect During an Inspection

As discussed in Part I, the FDA investigator or investigators must issue a 482 Notice of Inspection to the individual in charge. Investigators are not entitled to inspect until issuing the Notice of Inspection. 

During an inspection, investigators will typically commandeer a front room. They will spend most of their time here reviewing documents. This is the room where staff will speak to investigators and provide documentation.

What about site personnel? According to Niedelman, site personnel generally stay in a “back room” away from the investigators. This is the war room for site personnel (Niedelman refers to this as the “glue in an ongoing inspection”) where staff respond to requests from investigators and discuss how things are going in the front room. 

The back room “is generally where you will go to get educated as to what is going on before you walk into that front room.”

Figure 1 compares front room versus back room activities.

Figure 1 Front Room versus Back Room

What Should You Do?

Niedelman recommended site staff do the following:

  • Keep subject matter experts well-prepared
  • Select a note taker 
  • Track documents sent to the front room by date and time
  • Ensure all paper documents are tracked and keep copies of all papers given to the investigators
  • Make sure all resources and supplies requested are available
  • Listen carefully to all questions and only respond to those you know the answers to; if you do not know the answer, acknowledge the question and state you will get an answer

On the last point, Niedelman said that investigators will ask the same question in different ways because they want to ensure they are getting consistent answers. If personnel start giving different answers, investigators will suspect they are not getting the full truth.

“Do not be lured into a false sense of friendship,” he added. “Everything that you say is on the record. It may not appear on the 483, but it could appear in the inspection report that the investigator writes up.”

The back room “is generally where you will go to get educated as to what is going on before you walk into that front room.

What Will FDA Do During an Inspection?

Along with asking questions, the investigators will want to review documents, spending considerable time on this task. Documents they will review include:

  • Receipt and testing records of materials
  • Incoming inspection records
  • Production records
  • Testing equipment records
  • Equipment and maintenance records
  • Standard operating procedures

In addition, the investigators will also want to visit the production floor.

“They will walk the floor to make sure that you are, in fact, following those procedures,” Niedelman said. “Typically, most investigators will do a walkthrough at the end at the end of the session to get a feel for what is going on and what is being currently manufactured. They will frequently pick a product and follow it—generally, the most significant product being manufactured at the time of their inspection.”

As the investigators review documents, they may come across procedures they think do not reflect what actually occurs during production. In this case, they may revisit the production floor to verify compliance.

This is where mock audits come in handy. An hourly worker on the production line will likely be nervous when questioned by FDA. By conducting mock audits of staff, personnel become accustomed to the process.

If the investigators take any samples from your firm, they must provide a form 484 Receipt for samples and offer payment for the samples at wholesale price once the inspection is completed. 

Do not be lured into a false sense of friendship

Niedelman also warned against signing specific affidavits.

“Frequently they will attempt to obtain a signed affidavit to document distribution of a specific product and/or to document interstate commerce to establish their jurisdiction,” he said. “We recommend, as most law firms will, not to sign those affidavits. It is recommended that it not be signed and that you not allow them to read it to you. We have had clients that literally have walked out of a room where the investigator insisted on reading it.”

He added, “It is in your best interest not to sign those affidavits to document interstate commerce. You do not know what it is going to be used for. You do not know if it is just simply for jurisdiction or to document shipment of violative product. There is no requirement for you to sign.”

Part IV will look at what happens after an inspection along with some inspection do’s and dont’s. 

Get your CFR Trend Report from Redica

Download the Special Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica Pro Free

Sign up for your FREE account today and get instant access to:

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity
Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.